Exciting Developments in Weight-Loss Therapy: Terns Pharmaceuticals Sees 30% Stock Surge
Breakthrough in Weight-Loss Treatment
Terns Pharmaceuticals Inc. saw its stock surge by 30% early Monday after announcing positive results from an early-stage trial of its obesity treatment in pill form. The Phase 1 trial of TERN-601, a small-molecule GLP-1 receptor agonist, demonstrated statistically significant weight loss results, achieving a notable loss of up to 5.5% over 28 days.
Key Findings of the Trial
- The trial showcased strong dose-dependent weight loss.
- Participants received multiple-ascending doses.
- Maximum placebo-adjusted weight loss observed was 4.9%.
Being well-tolerated, the trial results position Terns Pharmaceuticals alongside established treatments like Wegovy, Ozempic, and Mounjaro, which are currently available in injectable form for diabetes and weight loss.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.